[go: up one dir, main page]

PL2708603T3 - Diagnostic and therapeutic uses of gelsolin in renal failure - Google Patents

Diagnostic and therapeutic uses of gelsolin in renal failure

Info

Publication number
PL2708603T3
PL2708603T3 PL13186249T PL13186249T PL2708603T3 PL 2708603 T3 PL2708603 T3 PL 2708603T3 PL 13186249 T PL13186249 T PL 13186249T PL 13186249 T PL13186249 T PL 13186249T PL 2708603 T3 PL2708603 T3 PL 2708603T3
Authority
PL
Poland
Prior art keywords
gelsolin
diagnostic
renal failure
therapeutic uses
therapeutic
Prior art date
Application number
PL13186249T
Other languages
Polish (pl)
Inventor
Ravi Thadhani
Thomas P. Stossel
Po-Shun Lee
Ananth Karumanchi
Original Assignee
Beth Israel Deaconess Medical Ct Inc
Massachusetts Gen Hospital
The Brigham And Women's Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beth Israel Deaconess Medical Ct Inc, Massachusetts Gen Hospital, The Brigham And Women's Hospital Inc filed Critical Beth Israel Deaconess Medical Ct Inc
Publication of PL2708603T3 publication Critical patent/PL2708603T3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4716—Muscle proteins, e.g. myosin, actin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
PL13186249T 2008-01-25 2009-01-23 Diagnostic and therapeutic uses of gelsolin in renal failure PL2708603T3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2378908P 2008-01-25 2008-01-25
EP13186249.2A EP2708603B1 (en) 2008-01-25 2009-01-23 Diagnostic and therapeutic uses of gelsolin in renal failure
EP09703176.9A EP2250280B1 (en) 2008-01-25 2009-01-23 Therapeutic uses of gelsolin in renal failure

Publications (1)

Publication Number Publication Date
PL2708603T3 true PL2708603T3 (en) 2017-12-29

Family

ID=40901583

Family Applications (2)

Application Number Title Priority Date Filing Date
PL09703176T PL2250280T3 (en) 2008-01-25 2009-01-23 Therapeutic uses of gelsolin in renal failure
PL13186249T PL2708603T3 (en) 2008-01-25 2009-01-23 Diagnostic and therapeutic uses of gelsolin in renal failure

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL09703176T PL2250280T3 (en) 2008-01-25 2009-01-23 Therapeutic uses of gelsolin in renal failure

Country Status (10)

Country Link
US (2) US9575072B2 (en)
EP (2) EP2708603B1 (en)
JP (2) JP5778425B2 (en)
CA (2) CA2749985C (en)
DK (2) DK2708603T3 (en)
ES (2) ES2531827T3 (en)
HU (1) HUE032875T2 (en)
PL (2) PL2250280T3 (en)
PT (2) PT2250280E (en)
WO (1) WO2009094194A2 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9408891B2 (en) 2003-11-12 2016-08-09 The Trustees Of The University Of Pennsylvania Methods of using gelsolin to treat or prevent bacterial sepsis
WO2005046454A2 (en) * 2003-11-12 2005-05-26 Trustrees Of The University Of Pennsylvania Methods of using gelsolin to treat or prevent bacterial sepsis
ES2730728T3 (en) 2004-05-12 2019-11-12 Brigham & Womens Hospital Inc Use of gelsolin to treat infections
JP2009530613A (en) * 2006-03-15 2009-08-27 ザ・ブリガム・アンド・ウイメンズ・ホスピタル・インコーポレイテッド Use of gelsolin to treat multiple sclerosis and to diagnose neurological diseases
ES2641879T3 (en) 2006-03-15 2017-11-14 The Brigham And Women's Hospital, Inc. Use of gelsolin to diagnose and treat inflammatory diseases
EP2535718B1 (en) 2007-05-11 2014-07-09 The Institutes for Pharmaceutical Discovery, LLC Methods for early diagnosis of kidney disease
CA2749985C (en) 2008-01-25 2020-07-07 The General Hospital Corporation Therapeutic use of gelsolin in chronic renal failure
WO2010025128A1 (en) * 2008-08-25 2010-03-04 Critical Biologics Corporation Methods for reducing sample size of clinical trials
ES2356217B1 (en) * 2009-08-04 2012-02-13 Universidad De Salamanca METHOD FOR DETECTION OF RENAL DAMAGE.
WO2015035405A1 (en) * 2013-09-09 2015-03-12 Pinta Biotherapeutics, Inc. Myostatin antagonist for treatment of pew in esrd patients
CN104004780A (en) * 2014-06-17 2014-08-27 南京大学 Method for expressing and purifying human cytoplasmic gelsolin
WO2016033187A1 (en) * 2014-08-26 2016-03-03 The Brigham And Women's Hospital, Inc. Use of gelsolin in the treatment and diagnosis of sickle cell disease
JP6947449B2 (en) * 2016-06-29 2021-10-13 学校法人自治医科大学 Biomarkers, diagnostic compositions, and diagnostic kits
CA3144272A1 (en) * 2019-06-21 2020-12-24 Bioaegis Therapeutics Inc. Compositions and synergistic methods for treating infections
US20230158107A1 (en) * 2020-05-04 2023-05-25 Bioaegis Therapeutics Inc. Methods and compositions for treating frailty

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5071773A (en) 1986-10-24 1991-12-10 The Salk Institute For Biological Studies Hormone receptor-related bioassays
CA2016227A1 (en) 1989-05-18 1990-11-18 Xandra O. Breakefield Genetic diagnosis of torsion dystonia
ATE171625T1 (en) * 1990-04-11 1998-10-15 Brigham & Womens Hospital THERAPEUTIC USE OF ACTIN-BINDING COMPOUNDS
US5464817A (en) 1990-04-11 1995-11-07 Brigham And Women's Hospital Method for reducing the viscosity of pathological mucoid airway contents in the respiratory tract comprising administering actin-binding compounds with or without DNASE I
AU8086191A (en) 1990-05-04 1991-11-27 Biogen, Inc. Multimeric gelsolin fusion constructs
US5571511A (en) 1990-10-22 1996-11-05 The U.S. Government Broadly reactive opsonic antibodies that react with common staphylococcal antigens
WO1992016192A1 (en) 1991-03-15 1992-10-01 Amgen Inc. Pulmonary administration of granulocyte colony stimulating factor
US5360350A (en) 1991-08-23 1994-11-01 The Whitaker Corporation Sealant compositions and sealed electrical connectors
AU4801393A (en) 1992-08-03 1994-03-03 New York University Cloning, expression and uses for neurocan as a chondroitin sulfate proteoglycan
US5691160A (en) 1992-08-14 1997-11-25 Biogen, Inc. Effects of actin filaments of fibrin clot structure and lysis
CA2144768A1 (en) 1992-10-01 1994-04-14 Stephen H. Friend Functional assay for tumor supressor genes
US5830436A (en) 1993-03-30 1998-11-03 Duke University Method of mucociliary clearance in cystic fibrosis patients using alkylaryl polyether alcohol polymers
US5593964A (en) 1993-10-07 1997-01-14 The George Washington University Medical Center Method of treating septic shock by preventing actin polymerization
JP3914272B2 (en) 1993-12-28 2007-05-16 中外製薬株式会社 Gene encoding adseverin
US5451569A (en) 1994-04-19 1995-09-19 Hong Kong University Of Science And Technology R & D Corporation Limited Pulmonary drug delivery system
US5563153A (en) 1995-02-22 1996-10-08 University Of Kansas Medical Center Sterile topical anesthetic gel
US5846743A (en) 1995-02-22 1998-12-08 Brigham And Women's Hospital, Inc. Polyphoshoinositide binding peptides for intracellular drug delivery
US6319498B1 (en) 1995-03-14 2001-11-20 Praecis Pharmaceuticals Incorporated Modulators of amyloid aggregation
US5804427A (en) 1995-05-19 1998-09-08 University Of Massachusetts Cytokine-, stress-, and oncoprotein-activated human protein kinase kinases
US5925529A (en) 1995-06-07 1999-07-20 The Regents Of The University Of California Method for discovery of peptide agonists
US5569588A (en) 1995-08-09 1996-10-29 The Regents Of The University Of California Methods for drug screening
US5750353A (en) 1995-12-11 1998-05-12 New England Medical Center Hospitals, Inc. Assay for non-peptide agonists to peptide hormone receptors
WO1998004589A2 (en) 1996-07-30 1998-02-05 Biogen, Inc. Production of recombinant plasma gelsolin containing a disulfide bond
WO1998024465A1 (en) 1996-12-04 1998-06-11 The Victoria University Of Manchester Wound healing and treatment of fibrosis
EP1003501B9 (en) 1997-04-02 2005-06-08 The Brigham And Women's Hospital, Inc. Use of an agent for lowering the risk of cardiovascular disease
AU3395900A (en) 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides
AU7912600A (en) 1999-10-06 2001-05-10 Basf Aktiengesellschaft Inhibitors of the endothelin signalling pathway and alphavbeta3 integrin receptor antagonists for combination therapy
AU2002225219A1 (en) 2001-01-26 2002-08-06 Oxford Glycosciences (Uk) Ltd Diagnosis and treatment of multiple sclerosis
EP1372720A4 (en) 2001-03-02 2006-07-26 Medimmune Inc Methods of preventing or treating inflammatory or autoimmune disorders by administering integrin alphav beta3 antagonists
EP1249244A1 (en) 2001-04-13 2002-10-16 Universiteit Gent Therapeutic compositions for the treatment of a disease modulated by the G-actin / F-actin equilibrium, especially a respiratory tract disease
BR0211062A (en) 2001-07-09 2004-07-20 Combinatorx Inc Combinations for the treatment of inflammatory disorders
WO2003020213A2 (en) 2001-08-30 2003-03-13 Praecis Pharmaceuticals Incorporated Methods and compositions for treating inflammatory disorders
US20080051348A1 (en) 2002-02-06 2008-02-28 Regenerx Biopharmaceuticals, Inc. Treatment of infections and other disorders
US20060089310A1 (en) 2002-02-06 2006-04-27 Regenerx Biopharmaceuticals, Inc. Treatment of infections and other disorders
WO2003088811A2 (en) 2002-04-16 2003-10-30 The Brigham And Women's Hospital, Inc. Gelsolin as a prognostic marker of artherosclerotic diseases
AU2003253014A1 (en) 2002-06-21 2004-01-06 Innogenetics N.V. Method for the diagnosis and differential diagnosis of neurological diseases
WO2004023973A2 (en) 2002-09-12 2004-03-25 Incyte Corporation Molecules for diagnostics and therapeutics
US20050048574A1 (en) 2003-03-14 2005-03-03 Kantor Aaron B. Biomarkers for diagnosing rheumatoid arthritis
GB0327723D0 (en) 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
US9408891B2 (en) 2003-11-12 2016-08-09 The Trustees Of The University Of Pennsylvania Methods of using gelsolin to treat or prevent bacterial sepsis
WO2005046454A2 (en) 2003-11-12 2005-05-26 Trustrees Of The University Of Pennsylvania Methods of using gelsolin to treat or prevent bacterial sepsis
CN1897965A (en) 2003-12-22 2007-01-17 雷金纳克斯生物制药公司 Method of treating or preventing biological or immunological responses to a reactive chemical or biological or toxic agent
EP1721163B1 (en) 2004-02-27 2015-04-29 Roche Diagnostics GmbH Method of assessing rheumatoid arthritis by measuring rheumatoid factor and interleukin-6
ES2730728T3 (en) 2004-05-12 2019-11-12 Brigham & Womens Hospital Inc Use of gelsolin to treat infections
JP2008501712A (en) 2004-06-04 2008-01-24 ジェネンテック・インコーポレーテッド Methods for treating multiple sclerosis
US20100062471A1 (en) 2005-09-29 2010-03-11 Ppd Biomarker Discovery Sciences Llc Biomarkers for Multiple Sclerosis and Methods of Use Thereof
ES2641879T3 (en) 2006-03-15 2017-11-14 The Brigham And Women's Hospital, Inc. Use of gelsolin to diagnose and treat inflammatory diseases
JP2009530613A (en) 2006-03-15 2009-08-27 ザ・ブリガム・アンド・ウイメンズ・ホスピタル・インコーポレイテッド Use of gelsolin to treat multiple sclerosis and to diagnose neurological diseases
CA2749985C (en) 2008-01-25 2020-07-07 The General Hospital Corporation Therapeutic use of gelsolin in chronic renal failure
KR101568323B1 (en) 2014-01-08 2015-11-12 한국원자력의학원 Composition for inducing maturation of dendritic cell comprising gelsolin and method of inducing the same
WO2016033187A1 (en) 2014-08-26 2016-03-03 The Brigham And Women's Hospital, Inc. Use of gelsolin in the treatment and diagnosis of sickle cell disease

Also Published As

Publication number Publication date
CA3080273C (en) 2022-11-22
EP2708603B1 (en) 2017-04-19
WO2009094194A3 (en) 2010-01-21
EP2708603A1 (en) 2014-03-19
CA2749985A1 (en) 2009-07-30
EP2250280B1 (en) 2014-12-03
DK2708603T3 (en) 2017-08-14
DK2250280T3 (en) 2015-03-09
JP2011510327A (en) 2011-03-31
ES2531827T3 (en) 2015-03-20
HUE032875T2 (en) 2017-11-28
EP2250280A2 (en) 2010-11-17
JP6042915B2 (en) 2016-12-14
US20090258830A1 (en) 2009-10-15
EP2250280A4 (en) 2011-02-16
CA3080273A1 (en) 2009-07-30
PT2250280E (en) 2015-03-04
WO2009094194A2 (en) 2009-07-30
ES2634263T3 (en) 2017-09-27
PL2250280T3 (en) 2015-06-30
US10272136B2 (en) 2019-04-30
JP5778425B2 (en) 2015-09-16
US20170189483A1 (en) 2017-07-06
JP2015121550A (en) 2015-07-02
US9575072B2 (en) 2017-02-21
PT2708603T (en) 2017-07-20
CA2749985C (en) 2020-07-07

Similar Documents

Publication Publication Date Title
PT2708603T (en) Diagnostic and therapeutic uses of gelsolin in renal failure
PL2115477T3 (en) Use of igfbp-7 in the assessment of heart failure
GB0801338D0 (en) Diagnostic context construction and comparison
HK1139733A1 (en) Diagnosis and risk stratification using nt-proet-1 nt-proet-1
HK1224375A1 (en) Use of mimecan in the assessment of heart failure mimecan
PL2564854T3 (en) Treatment of heart failure in non-human mammals with an aldosterone antagonist
GB0918392D0 (en) Diagnostic and therapeutic methods
GB2459076B (en) Improvements in and relating to medical devices
IL217209A0 (en) Novel antibodies and their uses in therapeutic and diagnostic methods
GB2460178B (en) Depsipeptides and their therapeutic use
GB0908875D0 (en) Depsipeptides and their therapeutic use
ZA201203286B (en) Therapeutic and diagnostic applications against trypanosomosis
GB0905970D0 (en) Depsipeptides and their therapeutic use
GB0807694D0 (en) Improvements in and relating to connection devices
HK1172649A1 (en) Improved human long pentraxin expression system and uses thereof
GB2460180B (en) Depsipeptides and their therapeutic use
GB0812293D0 (en) Improvements in and relating to construction
GB0909944D0 (en) Therapeutic agent and assay
GB0802458D0 (en) Improvements in or relating to medical treatments
AU2009900783A0 (en) Therapeutic and diagnostic agents
GB201006918D0 (en) Glycosylated agents and their use in therapy
AU2008906524A0 (en) Diagnostic and therapeutic agents
GB0819103D0 (en) Raphaine compounds and their use in therapy
GB0909344D0 (en) Drug composition and its uses in therapy
GB0809328D0 (en) Depsipeptides and their therapeutic use